Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;45(7):1521-1531.
doi: 10.1038/s41366-021-00816-3. Epub 2021 May 3.

Extensive weight loss reduces glycan age by altering IgG N-glycosylation

Affiliations

Extensive weight loss reduces glycan age by altering IgG N-glycosylation

Valentina L Greto et al. Int J Obes (Lond). 2021 Jul.

Abstract

Background: Obesity, a major global health problem, is associated with increased cardiometabolic morbidity and mortality. Protein glycosylation is a frequent posttranslational modification, highly responsive to inflammation and ageing. The prospect of biological age reduction, by changing glycosylation patterns through metabolic intervention, opens many possibilities. We have investigated whether weight loss interventions affect inflammation- and ageing-associated IgG glycosylation changes, in a longitudinal cohort of bariatric surgery patients. To support potential findings, BMI-related glycosylation changes were monitored in a longitudinal twins cohort.

Methods: IgG N-glycans were chromatographically profiled in 37 obese patients, subjected to low-calorie diet, followed by bariatric surgery, across multiple timepoints. Similarly, plasma-derived IgG N-glycan traits were longitudinally monitored in 1680 participants from the TwinsUK cohort.

Results: Low-calorie diet induced a marked decrease in the levels of IgG N-glycans with bisecting GlcNAc, whose higher levels are usually associated with ageing and inflammatory conditions. Bariatric surgery resulted in extensive alterations of the IgG N-glycome that accompanied progressive weight loss during 1-year follow-up. We observed a significant increase in digalactosylated and sialylated glycans, and a substantial decrease in agalactosylated and core fucosylated IgG N-glycans (adjusted p value range 7.38 × 10-04-3.94 × 10-02). This IgG N-glycan profile is known to be associated with a younger biological age and reflects an enhanced anti-inflammatory IgG potential. Loss of BMI over a 20 year period in the TwinsUK cohort validated a weight loss-associated agalactosylation decrease (adjusted p value 1.79 × 10-02) and an increase in digalactosylation (adjusted p value 5.85 × 10-06).

Conclusions: Altogether, these findings highlight that weight loss substantially affects IgG N-glycosylation, resulting in reduced glycan and biological age.

PubMed Disclaimer

Conflict of interest statement

Tamara Štambuk Declaration of interest: Dr. Štambuk reports that she is an employee of Genos Glycoscience Research Laboratory which offers commercial service of glycomic analysis and has several patents in the field. Helena Deriš Declaration of interest: Helena Deriš reports that she is an employee of Genos Glycoscience Research Laboratory which offers commercial service of glycomic analysis and has several patents in the field. Ana Cindrić Declaration of interest: Ana Cindrić reports that she is an employee of Genos Glycoscience Research Laboratory which offers commercial service of glycomic analysis and has several patents in the field. Frano Vučković Declaration of interest: Dr. Vučković reports that he is an employee of Genos Glycoscience Research Laboratory which offers commercial service of glycomic analysis and has several patents in the field. Olga Gornik Declaration of interest: Dr. Gornik reports that she is an employee of Genos Glycoscience Research Laboratory which offers commercial service of glycomic analysis and has several patents in the field. Alessandra Geremia Declaration of interest: Dr. Geremia reports grants from Wellcome Trust, grants from NIHR research capability fund, during the conduct of the study; other from UCB Pharma, outside the submitted work. Gordan Lauc Declaration of interest: Dr. Lauc reports that he is founder and owner of Genos LTD Zagreb; In addition, Dr. Lauc has multiple patents in the field of glycoscience pending or issued. Valentina L. Greto, Ana Cvetko, Niall J. Dempster, Mario Falchi, Cristina Menni, Jeremy W. Tomlinson, Domagoj Kifer, Bruno Sgromo, Richard S. Gillies, Tim Spector, Cristina Menni, Carolina V. Arancibia-Cárcamo Declarations of interest: none.

Figures

Fig. 1
Fig. 1. Bariatric surgery-related alterations in IgG N-glycosylation features over time (months).
Standardised glycan measurements are represented on the y-axis, while time in months is presented on the x-axis. IgG N-glycosylation altered features: G0 – agalactosylation; G1 – monogalactosylation; G2 – digalactosylation; S total – total sialylation; S1 – monosialylation; S2 – disialylation; CF – core fucosylation; B – incidence of bisecting N-acetylglucosamine. Red line – significant decrease; green line – significant increase; blue line – non-significant change.
Fig. 2
Fig. 2. BMI-associated alterations in IgG N-glycosylation across multiple timepoints.
Changes in IgG N-glycosylation derived traits are presented with lineplots of hypothetical ageing of TwinsUK participants (all women). Black dot represents a starting point of a 30-year-old woman, black triangle of a 40-year-old woman and black square of a 50-year-old woman. All of these women have a baseline BMI of 25 kg/m2. Blue lines represent age-related IgG N-glycosylation changes attributed to stabile BMI. Green lines represent age-related IgG N-glycosylation changes attributed to increasing BMI (0.5 kg/m2 per year, through a period of 10 years). Red lines represent age-related IgG N-glycosylation changes attributed to decreasing BMI (0.5 kg/m2 per year, through a period of 10 years). Highlighted areas represent 95% confidence intervals. The effect of age on IgG N-glycosylation is represented with the curve slope, while the effect of BMI change is represented with the distance of green/red line from the blue line.

References

    1. Obesity and overweight. [cited 2020 Apr 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
    1. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016;5:2048004016633371. - PMC - PubMed
    1. Alpert A, Pickman Y, Leipold M, Rosenberg-Hasson Y, Ji X, Gaujoux R, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med. 2019;25:487–95. doi: 10.1038/s41591-019-0381-y. - DOI - PMC - PubMed
    1. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576–90. doi: 10.1038/s41574-018-0059-4. - DOI - PubMed
    1. Touch S, Clément K, André ST. Cell populations and functions are altered in human obesity and type 2 diabetes. Curr Diab Rep. 2017;17:81. doi: 10.1007/s11892-017-0900-5. - DOI - PubMed

Publication types